Twist Bioscience signals $123M-$124M Q4 revenue as fiscal 2026 outlook rises to $456M-$457M (NASDAQ:TWST)

Twist Bioscience (TWST) delivered record Q3 revenue and raised full-year FY2026 guidance materially, signaling sustained momentum in synthetic biology and gene synthesis markets. The $123M–$124M Q4 revenue signal and $456M–$457M full-year target represent confident execution and widening addressable opportunities beyond traditional genomics into AI-enabled drug discovery.

Guidance raises are high-confidence signals when paired with record quarterly results, suggesting TWST's core business—synthetic DNA and RNA production—faces durable demand. The explicit mention of AI drug discovery expansion indicates management sees structural tailwinds from pharmaceutical sector automation, a narrative that has driven biotech valuations higher across 2024–2025.

The magnitude of upside revision (vs. prior range) and record-setting quarter reduce execution risk and validate TWST's competitive position in a consolidating synthetic biology space. Investors interpret such moves as evidence of pricing power and customer stickiness, both attractive in growth biotech infrastructure.

Sector implication: Health Care and technology-enabled biotech benefit from AI adoption acceleration in drug discovery workflows. TWST's guidance strength may signal broader health care IT and biotech infrastructure strength, potentially triggering rotation into genomics and synthetic biology plays alongside traditional large-cap pharma.